160 related articles for article (PubMed ID: 6102776)
1. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects.
Angrist B; Rotrosen J; Gershon S
Psychopharmacology (Berl); 1980 Jan; 67(1):31-8. PubMed ID: 6102776
[TBL] [Abstract][Full Text] [Related]
2. Amphetamine response and relapse risk after depot neuroleptic discontinuation.
Angrist B; Peselow E; Rubinstein M; Wolkin A; Rotrosen J
Psychopharmacology (Berl); 1985; 85(3):277-83. PubMed ID: 2860683
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.
Angrist B; Rotrosen J; Gershon S
Psychopharmacology (Berl); 1980; 72(1):17-9. PubMed ID: 6110217
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Markianos M; Hatzimanolis J; Lykouras L
Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
[TBL] [Abstract][Full Text] [Related]
5. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
[TBL] [Abstract][Full Text] [Related]
7. Acute and chronic effects of neuroleptics and acute effects of apomorphine and amphetamine on dopamine turnover in corpus striatum and substantia nigra of the rat brain.
Nicolaou NM
Eur J Pharmacol; 1980 Jun; 64(2-3):123-32. PubMed ID: 6105080
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
9. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
10. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
11. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
12. The effects of some atypical neuroleptics on apomorphine-induced behaviors as a measure of their relative potencies in blocking presynaptic versus postsynaptic dopamine receptors.
Robertson A; MacDonald C
Pharmacol Biochem Behav; 1986 Jun; 24(6):1639-43. PubMed ID: 2874567
[TBL] [Abstract][Full Text] [Related]
13. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
Asato N; Hirayasu Y; Hiramatsu K; Ohta H
Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
[TBL] [Abstract][Full Text] [Related]
14. Differential response to amphetamine in schizophrenia.
Cesarec Z; Nyman AK
Acta Psychiatr Scand; 1985 May; 71(5):523-38. PubMed ID: 2861718
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
[TBL] [Abstract][Full Text] [Related]
16. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
17. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Janssen PA; Awouters FH
Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
[TBL] [Abstract][Full Text] [Related]
18. Increased blink rates in schizophrenics. Influences of neuroleptics and psychopathology.
Mackert A; Flechtner KM; Woyth C; Frick K
Schizophr Res; 1991; 4(1):41-7. PubMed ID: 1672606
[TBL] [Abstract][Full Text] [Related]
19. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
Havemann U
Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
[No Abstract] [Full Text] [Related]
20. High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients.
Nestoros JN; Nair NP; Pulman JR; Schwartz G; Bloom D
Psychopharmacology (Berl); 1983; 81(1):42-7. PubMed ID: 6138791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
